Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SIGLEC21P is classified as a pseudogene, specifically the sialic acid binding Ig-like lectin 21, pseudogene. Pseudogenes are DNA sequences similar to known genes but are not functional due to disabling mutations, and they do not encode functional proteins[1][5][4][6]. The SIGLEC (sialic acid-binding immunoglobulin-like lectin) family generally encodes cell surface receptors that modulate immune responses, but SIGLEC21P itself is nonfunctional, lacking evidence of a protein product or biological activity in humans[1][4][5]. It is not a therapeutic target, receptor, or functional gene product in humans, and there is no literature reporting any drug interactions, disease associations, or physiological role for SIGLEC21P. Therefore, it should not be considered a valid or actionable molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid binding Ig-like lectin 21, pseudogene (SIGLEC21P).